Cargando…

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

Detalles Bibliográficos
Autores principales:	Gerds, Aaron T., Bose, Prithviraj, Hobbs, Gabriela S., Kuykendall, Andrew T., Neilson, Lynn M., Song, Jinlin, Klencke, Barbara, Harrison, Claire N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529047/ https://www.ncbi.nlm.nih.gov/pubmed/36204692 http://dx.doi.org/10.1097/HS9.0000000000000778

Ejemplares similares

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
por: Harrison, Claire, et al.
Publicado: (2023)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
por: Asou, Mea, et al.
Publicado: (2021)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
por: Mesa, Ruben A., et al.
Publicado: (2023)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
por: Sureau, Léa, et al.
Publicado: (2021)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
por: Lisette, Del Corso, et al.
Publicado: (2013)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
por: Siriwaseree, Jeeraprapa, et al.
Publicado: (2022)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

The Janus face of N-terminal lysines in α-synuclein
por: Uceda, Ana Belén, et al.
Publicado: (2020)

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial
por: Zhang, Yi, et al.
Publicado: (2022)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
por: Miyawaki, Hiroshi, et al.
Publicado: (2019)

The Janus face of DNA methylation in aging
por: Mugatroyd, Chris, et al.
Publicado: (2010)

The anemic cat
por: Lappin, Michael R.
Publicado: (2006)

The Art of Oncology: COVID‐19 Era
por: Reynolds, Kerry L., et al.
Publicado: (2020)

A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis
por: Migliaccio, Anna Rita
Publicado: (2021)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Mechanism of Anemic Murmurs
por: Rochester, DeLancey
Publicado: (1890)

Determinants for Anemic Retinopathy
por: Venkatesh, Ramesh, et al.
Publicado: (2023)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t6rdfb7s4uaes57utsauti6muj